Robert Ghenchev

Director/Board Member at EXSCIENTIA PLC

43 year

Health Technology

Finance

Technology Services

Profile

Robert Ghenchev is currently Director at Mission Bio, Inc., Exscientia AI Ltd., Exscientia Ltd., Mightyowl, Inc., and Quanta Dialysis Technologies LLC.
Mr. Ghenchev is also Head-Growth Equity at Novo Holdings Equity US, Inc. since 2025.
Former roles include Director at Tempus AI, Inc., Non-Executive Director at Oxford Biomedica Plc from 2019 to 2025, Senior Vice President at Moelis & Company UK LLP from 2010 to 2018, and Managing Partner at Novo Growth from 2018 to 2025.
Education includes a graduate degree from the University of Oxford in 2007 and an undergraduate degree from McGill University in 2006.

Robert Ghenchev active positions

Companies	Position	Start
EXSCIENTIA PLC	Director/Board Member	01/05/2020
Exscientia AI Ltd. Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Provides AI and machine learning techniques based drug discovery services	Director/Board Member	01/05/2020
Mission Bio, Inc. Mission Bio, Inc. BiotechnologyHealth Technology Develops single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development	Director/Board Member	-
Mightyowl, Inc. Mightyowl, Inc. Internet Software/ServicesTechnology Services Operates as an online educational platform	Director/Board Member	-
Novo Holdings Equity Us, Inc. Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies	Corporate Officer/Principal	21/03/2025
Quanta Dialysis Technologies, Inc. Quanta Dialysis Technologies, Inc. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies, Inc. is an American medical technology company focused on transforming kidney care through its dialysis system. The company is located in the US. The platform supports all major hemodialysis modalities, including intermittent hemodialysis, sustained low efficiency dialysis, continuous renal replacement therapy, and home hemodialysis, delivered from a single, compact, portable device without the need for dialysate bags. The system uses disposable cartridge-based dialysate technology that eliminates daily rinses and harsh chemical disinfections, requiring only a once-weekly hot rinse, and offers flexible prescription options with easy training and minimal maintenance. It is designed for use in clinics, ICUs, post-acute care, and home settings, and features a lightweight, space-saving design with an intuitive touchscreen interface. The Quanta cart accessory enhances mobility and modularity for bedside treatments and is compatible with portable reverse osmosis units. The company also provides a digital health platform, CareLinq, for real-time machine connectivity, operational excellence, fleet management, and staff e-learning. Quanta holds worldwide patents and registered trademarks protecting its technology and branding, and its technology is supported by published clinical research and validated through clinical trials.	Director/Board Member	-

All active positions of Robert Ghenchev

Former positions of Robert Ghenchev

Companies	Position	End
Novo Growth Novo Growth Investment ManagersFinance Novo Growth invests in companies located across the globe. The firm focuses on companies operating in the fields of life science, technology, industrial biotechnology, complex manufacturing and supply chain sectors and industries. It participates in growth transactions with an investment size of USD 30 - 100 million.	Private Equity Investor	01/11/2025
OXFORD BIOMEDICA PLC	Director/Board Member	20/10/2025
Moelis & Co. (UK) LLP Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services	Corporate Officer/Principal	01/01/2018
░░░░░░ ░░░ ░░░░	░░░░░░░░░░░░░░ ░░░░░░	-

See the detail of Robert Ghenchev's experience

Education of Robert Ghenchev

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robert Ghenchev's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	12
Oxford Biomedica Plc Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields	Health Technology
University of Oxford University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
McGill University McGill University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Moelis & Co. (UK) LLP Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services	Finance
Tempus AI, Inc. Tempus AI, Inc. Packaged SoftwareTechnology Services Develops AI platform for clinical and molecular data testing	Technology Services
Mission Bio, Inc. Mission Bio, Inc. BiotechnologyHealth Technology Develops single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development	Health Technology
Exscientia AI Ltd. Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Provides AI and machine learning techniques based drug discovery services	Health Technology
Novo Growth Novo Growth Investment ManagersFinance Novo Growth invests in companies located across the globe. The firm focuses on companies operating in the fields of life science, technology, industrial biotechnology, complex manufacturing and supply chain sectors and industries. It participates in growth transactions with an investment size of USD 30 - 100 million.	Finance
Exscientia Plc Exscientia Plc Packaged SoftwareTechnology Services Function as an investment holding company whose subsidiaries provides artificial intelligence and machine learning services	Technology Services
Mightyowl, Inc. Mightyowl, Inc. Internet Software/ServicesTechnology Services Operates as an online educational platform	Technology Services
Novo Holdings Equity Us, Inc. Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies	Finance
Quanta Dialysis Technologies, Inc. Quanta Dialysis Technologies, Inc. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies, Inc. is an American medical technology company focused on transforming kidney care through its dialysis system. The company is located in the US. The platform supports all major hemodialysis modalities, including intermittent hemodialysis, sustained low efficiency dialysis, continuous renal replacement therapy, and home hemodialysis, delivered from a single, compact, portable device without the need for dialysate bags. The system uses disposable cartridge-based dialysate technology that eliminates daily rinses and harsh chemical disinfections, requiring only a once-weekly hot rinse, and offers flexible prescription options with easy training and minimal maintenance. It is designed for use in clinics, ICUs, post-acute care, and home settings, and features a lightweight, space-saving design with an intuitive touchscreen interface. The Quanta cart accessory enhances mobility and modularity for bedside treatments and is compatible with portable reverse osmosis units. The company also provides a digital health platform, CareLinq, for real-time machine connectivity, operational excellence, fleet management, and staff e-learning. Quanta holds worldwide patents and registered trademarks protecting its technology and branding, and its technology is supported by published clinical research and validated through clinical trials.	Health Technology